- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheumatologie»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2019 | Daily Highlights
SSc with pulmonary hypertension
SAFETY AND EFFICACY OF B-CELL DEPLETION WITH RITUXIMAB FOR THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN A MULTI-CENTER NIH CLINICAL TRIAL
Abstract: 867
Authors: M. Nicolls et al.
Key content:
Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have implicated immune dysregulation and B cell activation in the pathogenesis of both SSc and PAH. 57 SSc patients were randomized to rituximab or placebo. Six minute walk test data demonstrated ambiguous data but on average rituximab fared better with regards to pulmonary vascular resistance.
Relevance:
This is the first controlled trial examining the role of immunotherapy for SSc-PAH. B cell depletion is potentially effective and warrants further study, as are other immunosuppressive strategies.
Zusammenfassung und Kommentar von:
Prof. Dr. Ulrich Walker
Basel
